Overview
Investors searching INJ vs AKT usually want a clear market-cap and momentum snapshot. Injective prints $5.13 (+3.91%) while AKT is at $1,882.43 (-2.20%), with volume edge currently on AKT.
Quick winners
Full comparison
| Metric | INJ | AKT |
|---|---|---|
| Price | $5.13 | $1,882.43 |
| Market Cap | $490.41M | $138.25M |
| FDV | — | — |
| Volume 24h | $2.59M | $3.73M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 208.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | AKT |
|---|---|---|
| 1H | — | — |
| 24H | +3.91% | -2.20% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | AKT |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 59.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Automated technical notes for this pair highlight neutral conditions on INJ and bearish on AKT. Volatility differences can amplify short-term gaps.
Fundamentals
| Metric | INJ | AKT |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
AKT
Pros and cons
Pros of Injective
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Higher ranking for Injective can translate into tighter spreads on major venues.
Cons of Injective
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
Pros of AKT
- PEPS tracking for AKT still includes AI score and level context for monitoring.
- AKT can offer higher relative beta when market attention rotates toward its niche.
- Diversifying versus Injective with AKT can change portfolio factor exposure.
- If technical momentum aligns, AKT may outperform on medium-term windows.
Cons of AKT
- Higher volatility on AKT cuts both ways and demands stricter risk limits.
- Trend failures on AKT often travel faster than on more established assets.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
Across winners above, no single coin dominates every column. Prefer scenarios: trend continuation favors the side with aligned momentum; mean-reversion favors the side stretched on RSI.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #99; AKT shows $138.25M and #208. Where liquidity and flow matter, watch AKT. Where durability matters, watch Injective. AI composite scores (48.70/58.20) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or AKT?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or AKT?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and AKT.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. AKT currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.